By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Macquarie Capital today downgraded Illumina's stock to Underperform, saying the company faces substantial headwinds moving ahead, including cuts in academic and government funding, excess large-scale sequencing capacity, and an "at best" flat microarray business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.